PERSPECTIVE
The management of cytomegalovirus retinitis in AIDS Baljean Dhillon Cytomegalovirus (CMV) shares many properties with other members of the herpesvirus family -it exhibits latency, reactivates under suitable conditions to cause human disease, and it is incurable. CMV is the primary opportunistic viral infection in the immunosuppressed person and gives rise to a wide spectrum of disease. CMV is a major cause of morbidity and mortality among patients with AIDS, and the retina is the commonest site of infection.' Cytomegalovirus retinitis (CMVR) may be the AIDS defining diagnosis though more commonly occurs months after the diagnosis of AIDS. If left untreated, patients with unilateral CMVR are likely to develop disease in their second eye and ultimately become blind.2 It has now become accepted practice to treat sight threatening CMVR with either ganciclovir or foscarnet, which are effective in delaying the progress ofthis destructive infection. Systemic treatment for CMV disease also reduces extraretinal CMV related morbidity and mortality and subjectively improves quality of life.3 This review of the clinical management of CMVR in patients with AIDS also includes complications of therapy, and dilemmas which face the patient, physician, and ophthalmologist.
The use of antiretroviral agents together with the early recognition and treatment of opportunistic infection has led to the increased survival of patients with AIDS despite their profound immunodepletion. The median survival of patients with AIDS after the diagnosis of CMV disease is 1 year or longer,'4 and, as with other evolving statistics concerning CMVR, this is likely to underestimate the current clinical experience.' Given the increasing number of patients with HIV infection, and their longer survival, it is likely that CMVR will become an increasingly prevalent condition. A previous communication reported the increasing CMVR attack rate with prolonged survival, 6 and supports the impression that the majority of patients with AIDS would develop CMVR if they survived long enough.
Reports from the United States of CMVR prevalence ofup to 40% among patients with AIDS2378 vary widely due to differences in patient recruitment, detection method, and populations studied. Geographical variations in survival which relate to the availability and use of drugs to treat opportunistic infections would also influence the prevalence of CMVR. Studies carried out prospectively or post mortem would yield the most accurate prevalence data. Regional series from London and Edinburgh estimated the minimum risk of developing sight threatening CMVR among patients with AIDS as 17%,' despite differences between the two populations in terms of HIV transmission group. In Edinburgh 38% of AIDS is associated with homosexual/ bisexual behaviour, though this percentage constituted 75% of patients with CMVR in this region; this is probably a reflection of the higher prevalence of sexually acquired CMV infection. It could also represent greater immunosuppression in the homo/bisexual group because of the longer duration of infection.6 In this region CMVR is the index diagnosis in approximately 3% ofpatients with AIDS and 17% ofpatients with CMVR and AIDS.
Symptoms
In comparison with the more severe systemic symptoms associated with AIDS the onset of CMVR is associated with few visual symptoms; unless the patient is aware of their significance, relatively minor visual symptoms may be considered too trivial to disclose to his physician. In Edinburgh from a cohort of 24 patients with CMVR and AIDS, 16 had unilateral retinitis at presentation and, although 59% of this group had macula and/or optic nerve threatening disease, less than half the group showed visual symptoms.9 Visual blurring, photopsia, floaters, and scotomata are usually only noticed on occlusion of the unaffected eye, or when CMVR affects both eyes. Although untreated CMVR is relentlessly progressive, the spread is relatively slow, and may partly explain the absence of acute visual symptoms. The The management ofcytomegalovirus retinitis in AIDS Evaluation Close observation and accurate documentation of the retinal signs are the key to effective management of CMVR. The patients are often sick and unable to tolerate prolonged examination. Following assessment of the best corrected visual acuity, the pupils are dilated for fundus examination. The most important evaluation procedure is binocular indirect ophthalmoscopy. If a central focus of CMVR shows features ofquestionable activity and ifthe patient is able to sit at a slit-lamp, a hand held 78 dioptre or 90 dioptre lens is used to examine the fundi, which may then be photographed. Perimetry can be of use though few patients are able to perform it well. Correlation of the retinal appearance with a corresponding field defect supports the diagnosis of CMVR; this invariably produces an absolute scotoma which enlarges as the infection, progresses.'4 When photography is not possible, perimetry can be attempted. However, both photography and perimetry are of little value in mapping the progression of peripheral retinitis anterior to the equator, which is inaccessible to the fundus camera and may cause no scotoma. Also, it is not practical to perform photography or perimetry in patients with advanced AIDS who require bedside examination, and at this stage there is a high risk of recurrence. Therefore, it is always necessary to document not only the characteristics of the retinitis, as described above, but also precisely to record the site and extent of the CMVR by clear and accurate drawing. Holland et all' described a classification for recording the site which divides the retina into three zones -a posterior area which encompasses the disc and macula (zone 1), extending 3000 [tm from the fovea and 1500 itm from the disc; the midperipheral retina (zone 2) extending anterior to zone 1 up to the equator; and the far peripheral retina (zone 3) extending anterior to the equator. For peripheral CMVR the site is further defined by documenting the retinal site and clock hours involved; retinal vessels and vortex vein ampullae adjacent to the infection border served as landmarks to identify the demarcation line between affected and unaffected retina. The vascular landmarks adjacent to the CMVR border are noted, using the smallest visible arteriolar and venular branches to describe the boundary position, particularly the border closest to the macula and optic nerve.
Fundus fluorescein angiography This investigation is not necessary for the majority of patients. It may be helpful in distinguishing between CMVR and toxoplasmic retinochoroiditis if the clinical picture is uncertain. The fluorescein angiogram appearance of CMVR shows evidence ofretinal vascular occlusion and permeability alterations in the area of retinitis.'6 Hyperfluorescence starts at the centre, and extends to the borders, and the final hyperfluorescent area is smaller than the lesion observed on the red free photographs.'7 The underlying choroid is still present, and alterations in the retinal pigment epithelium produce this angiographic picture.
Toxoplasmic retinochoroiditis produces complete destruction of the retina and choroid, and angiography shows marked fluorescein staining without permeability changes or artery obstruction in the areas of focal periarterial exudate or plaques'6; inflammatory changes in the vitreous and anterior chamber'8 obscure the hyperfluorescence, which starts at the edge ofthe lesion and progresses towards the centre. The area of late hyperfluortscence is larger than the lesion seen on the control photographs. '7 Laboratory investigations Serological testing or isolation of CMV from the throat or urine are not required for making the diagnosis of CMVR, which is a sign of systemic infection. Of 24 patients with AIDS and CMVR studied in Edinburgh, 19 had raised CMV IgG levels indicating past infection, nine of whom also had detectable CMV IgM indicating newly acquired infection; 95% of homosexual men and 80% of HIV positive injecting drug users in Edinburgh show evidence of past CMV infection (Regional Virus Laboratory, unpublished results).
The development of in situ nucleic acid hybridisation and nucleic acid amplification by polymerase chain reactions will allow laboratory diagnosis on ocular fluids and tissue.19 20 Until these techniques are widely available ophthalmologists must rely on their clinical skills to distinguish between CMVR and other infections affecting the retina and/or the choroid, caused by toxoplasmosis, syphilis, candida, pneumocystis, varicella zoster, and herpes simplex, which may cause concurrent infection. This article does not intend to cover the wide spectrum of differential diagnoses, though the reader should become familiar with their distinguishing clinical features.
Treatment
In most instances the treatment for CMVR is for the duration of the patient's life and decisions regarding therapy should actively involve the patient and his partner. Even ifCMVR is peripheral and not immediately sight threatening, treatment should not be delayed; CMVR threatening the macula and disc should be treated immediately. A heavy commitment is required from the patient, ophthalmologist, and referring physician to monitor the therapeutic response and toxic effects of therapy for the duration of the patient's life. The problem of progressive CMVR during maintenance therapy remains a major management challenge.
Systemic therapy A controlled retrospective study of ganciclovir" confirmed previous uncontrolled reports of treatment benefit for CMVR. Foscarnet is also effective in slowing the progression of CMVR.2' Intravenous ganciclovir and foscarnet suppress, but do not eradicate CMV disease. Following high dose induction therapy for 2-3 weeks, long term maintenance therapy is necessary to prevent recurrence of CMVR, which nevertheless occurs in 18-54% of patients.22224 It is likely that all patients will relapse ifthe survival is sufficiently long25 though this generally responds to an increase in anti-CMV therapy. Both drugs are associated with toxic side effects, ganciclovir with bone marrow suppression and foscarnet with renal impairment, metabolic abnormalities, and seizure. Foscarnet therapy is associated with an increased survival period4; however, patients with impaired renal function had a longer survival with ganciclovir. Overall ganciclovir was better tolerated than foscarnet which requires a prolonged infusion time and the maintenance of adequate hydration is often poorly tolerated.
Partial or complete arrest ofactive CMVR occurs in almost all patients after induction therapy with ganciclovir at a dose of 10 mg/kg/day (two divided doses), or 180 mg/kg/day (three divided doses) of foscarnet.34 5 25 Other forms of local treatment include transscleral iontophoresis of foscarnet35 and laser photocoagulation to produce a barrier scar"6; these treatment modalities require further study but are exciting possibilities for the future.
Treatment toxicity
In most UK centres ganciclovir remains the first line therapy, though toxicity is a common problem. Ganciclovir associated neutropenia is often associated with concomitant zidovudine administration; the use of alternative antiretroviral agentsfor example, 2',3'-dideoxyinosine (ddi) -may lead to a reduction in this side effect. Ganciclovir associated myelotoxicity should be managed by the following strategies: * withholding zidovudine * using haematological stimulating factors (G-CSF) * replacing ganciclovir with foscarnet * using a combination of foscarnet and ganciclovir * intravitreal therapy Response to therapy Following the initiation of treatment for CMVR, ophthalmoscopic monitoring ofboth eyes is necessary and the guidelines described below for the timing of ophthalmic examination are based on local experience. Changes in the appearance of the border infection usually accompany a response to induction therapy, and patients should be examined weekly during this period. After the first week of treatment signs of active CMVR may still be present with oedematous, opaque, and variably haemorrhagic retina at the infected boundary. By the second or third week of induction a healing response is seen with decreased opacification at the infected border and a more granular appearance to the retina with resolution of the satellite spots; most importantly, failure of the borders to advance signifies infection control. Cessation in centrifugal spread of CMVR is the major criterion used to assess a therapeutic response as altered border characteristics may not be a reliable sign of non-progression. Thereafter, the frequency of follow up is determined by factors such as the site, laterality, control of infection (cessation of CMVR spread), and the appearance of the CMVR border. If the CMVR border is close to and threatening the macula/optic nerve, with signs of border activity and advancement, frequent follow up every 1-2 weeks is necessary. Ifthere is no sign of progression, and the border looks inactive follow up might be lengthened to 4-6 weekly; patients with bilateral CMVR are more likely to relapse during maintenance therapy9 and should be followed more frequently. A reduction in the frequency of maintenance treatment from 7 to 5 days per week should only be considered for patients with stable and inactive CMVR. Further reduction is likely to lead to relapse. A 
